American Pharmaceutical Partners (Schaumburg, Ill) recently received FDA approval for its abbreviated new drug application for Ampicillin and Sulbactam for Injection. The product is the generic equivalent of Pfizer Inc's Unasyn. Ampicillin and Sulbactam is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium. The product is indicated for the treatment of several skin and skin structure, intra-abdominal, and gynecologic infections due to susceptible strains of microorganisms. Administered intravenously or intramuscularly, Ampicillin and Sulbactam for Injection is available in 1.5-and 3-g single-dose vials. The product is preservative-free, and each vial will include a bar code and latex-free vial stopper. For more information, visit www.appdrugs.com.